Acadian Asset Management LLC Acquires New Position in Esperion Therapeutics Inc (NASDAQ …

Acadian Asset Management LLC purchased a new position in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) during the 2nd quarter, …

Esperion Therapeutics logoAcadian Asset Management LLC purchased a new position in shares of Esperion Therapeutics Inc (NASDAQ:ESPR) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 17,047 shares of the biopharmaceutical company’s stock, valued at approximately $793,000. Acadian Asset Management LLC owned 0.06% of Esperion Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of ESPR. Wasatch Advisors Inc. boosted its holdings in shares of Esperion Therapeutics by 13.4% in the first quarter. Wasatch Advisors Inc. now owns 637,789 shares of the biopharmaceutical company’s stock valued at $25,607,000 after acquiring an additional 75,165 shares in the last quarter. Pictet Asset Management Ltd. raised its holdings in Esperion Therapeutics by 13.6% in the 1st quarter. Pictet Asset Management Ltd. now owns 437,518 shares of the biopharmaceutical company’s stock valued at $17,566,000 after acquiring an additional 52,467 shares in the last quarter. Spark Investment Management LLC raised its holdings in Esperion Therapeutics by 72.1% in the 1st quarter. Spark Investment Management LLC now owns 390,900 shares of the biopharmaceutical company’s stock valued at $15,694,000 after acquiring an additional 163,800 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in Esperion Therapeutics by 4.0% in the 2nd quarter. Pinnacle Associates Ltd. now owns 187,549 shares of the biopharmaceutical company’s stock valued at $8,725,000 after acquiring an additional 7,225 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in Esperion Therapeutics by 73.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 140,825 shares of the biopharmaceutical company’s stock valued at $6,875,000 after acquiring an additional 59,425 shares in the last quarter.

ESPR traded down $0.18 on Friday, hitting $36.56. The company’s stock had a trading volume of 279,136 shares, compared to its average volume of 435,372. Esperion Therapeutics Inc has a 12 month low of $33.13 and a 12 month high of $60.99. The company has a quick ratio of 5.65, a current ratio of 5.65 and a debt-to-equity ratio of 0.01. The firm has a market cap of $998.52 million, a P/E ratio of -4.85 and a beta of 1.71. The company’s 50 day simple moving average is $37.78 and its 200-day simple moving average is $44.26.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.86) by ($0.15). The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.05 million. During the same quarter in the previous year, the company earned ($1.71) EPS. Esperion Therapeutics’s quarterly revenue was up 9720.0% on a year-over-year basis. Equities analysts predict that Esperion Therapeutics Inc will post -3.02 earnings per share for the current fiscal year.

Several equities research analysts have recently weighed in on ESPR shares. ValuEngine lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, September 5th. Cowen reaffirmed a “buy” rating and set a $80.00 price target on shares of Esperion Therapeutics in a research report on Thursday, July 18th. Goldman Sachs Group cut shares of Esperion Therapeutics from a “neutral” rating to a “sell” rating and set a $50.00 price target on the stock. in a research report on Wednesday, May 29th. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 13th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $74.00.

In related news, major shareholder Target N. V. Biotech acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The stock was purchased at an average price of $42.65 per share, with a total value of $2,132,500.00. Following the transaction, the insider now owns 3,572,964 shares of the company’s stock, valued at approximately $152,386,914.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Timothy M. Mayleben acquired 2,500 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were bought at an average cost of $35.25 per share, with a total value of $88,125.00. Following the transaction, the chief executive officer now directly owns 76,015 shares in the company, valued at approximately $2,679,528.75. The disclosure for this purchase can be found here. Insiders have bought 147,500 shares of company stock valued at $5,521,825 over the last three months. 7.70% of the stock is owned by corporate insiders.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Story: Momentum Investing

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Esperion Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

5 of Today’s Biggest Marijuana Stock Losers – Thursday, September 12, 2019

Today, shares of Aurora Cannabis Inc closed the trading day down at $5.89 per share. When compared to the previous close of $6.47 per share, …

Out of over 200+ marijuana-related stocks out there, here are just 5 of the biggest gainers in trading today on Thursday, September 12, 2019 including Aurora Cannabis Inc (NYSE:ACB) and more…

Aurora Cannabis Inc (NYSE:ACB)

Today, shares of Aurora Cannabis Inc closed the trading day down at $5.89 per share. When compared to the previous close of $6.47 per share, today’s decrease of -$0.58 per share represents an approximate -8.96% drop in price for shares of ACB.

Cresco Labs Inc (OTC:CRLBF)

Today, shares of Cresco Labs Inc closed the trading day down at $8.08 per share. When compared to the previous close of $8.80 per share, today’s decrease of -$0.72 per share represents an approximate -8.18% drop in price for shares of CRLBF.

DionyMed Brands Inc (OTC:DYMEF)

Today, shares of DionyMed Brands Inc closed the trading day down at $0.65 per share. When compared to the previous close of $0.70 per share, today’s decrease of -$0.05 per share represents an approximate -7.14% drop in price for shares of DYMEF.

Origin House Group (OTC:ORHOF)

Today, shares of Origin House Group closed the trading day down at $6.09 per share. When compared to the previous close of $6.60 per share, today’s decrease of -$0.51 per share represents an approximate -7.73% drop in price for shares of ORHOF.

Valens Groworks Corp (OTC:VGWCF)

Today, shares of Valens Groworks Corp closed the trading day down at $2.60 per share. When compared to the previous close of $2.88 per share, today’s decrease of -$0.28 per share represents an approximate -9.72% drop in price for shares of VGWCF.

Be sure to subscribe to updates here so you never miss an important update.

Get Real-Time Updates from The Daily Marijuana Observer

Related Posts:

  • No Related Posts

Golden Minerals Co (NYSEAMERICAN:AUMN) Short Interest Up 11.4% in August

Vanguard Group Inc. increased its stake in Golden Minerals Co (NYSEAMERICAN:AUMN) (TSE:AUM) by 4.6% in the second quarter, according to the …

Golden Minerals logoGolden Minerals Co (NYSEAMERICAN:AUMN) (TSE:AUM) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 2,181,800 shares, an increase of 11.4% from the July 15th total of 1,957,800 shares. Based on an average trading volume of 400,800 shares, the days-to-cover ratio is presently 5.4 days. Currently, 4.2% of the company’s stock are short sold.

Shares of NYSEAMERICAN:AUMN remained flat at $$0.27 during trading on Wednesday. The company’s stock had a trading volume of 237,698 shares, compared to its average volume of 274,658. Golden Minerals has a 12-month low of $0.19 and a 12-month high of $0.38.

Golden Minerals (NYSEAMERICAN:AUMN) (TSE:AUM) last announced its earnings results on Wednesday, August 7th. The basic materials company reported ($0.03) earnings per share for the quarter.

Separately, HC Wainwright reiterated a “buy” rating and set a $0.60 target price on shares of Golden Minerals in a research note on Thursday, August 8th.

An institutional investor recently raised its position in Golden Minerals stock. Vanguard Group Inc. increased its stake in Golden Minerals Co (NYSEAMERICAN:AUMN) (TSE:AUM) by 4.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 958,728 shares of the basic materials company’s stock after acquiring an additional 42,160 shares during the period. Vanguard Group Inc. owned about 0.98% of Golden Minerals worth $271,000 as of its most recent SEC filing.

Golden Minerals Company Profile

Golden Minerals Company, an exploration stage company, engages in mining, construction, and exploration of mineral properties. It explores for gold, silver, zinc, lead, and other minerals. The company owns 100% interest in the Velardeña and Chicago precious metals mining properties in the State of Durango, Mexico; and the El Quevar advanced silver exploration property in the province of Salta, Argentina.

Recommended Story: Insider Trading – What You Need to Know

Receive News & Ratings for Golden Minerals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Golden Minerals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

SG Americas Securities LLC Has $1.15 Million Stock Holdings in Finisar Co. (NASDAQ:FNSR)

SG Americas Securities LLC decreased its position in shares of Finisar Co. (NASDAQ:FNSR) by 47.9% in the second quarter, according to its most …

Finisar logoSG Americas Securities LLC decreased its position in shares of Finisar Co. (NASDAQ:FNSR) by 47.9% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,466 shares of the technology company’s stock after selling 46,345 shares during the quarter. SG Americas Securities LLC’s holdings in Finisar were worth $1,154,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Alpine Associates Management Inc. lifted its stake in shares of Finisar by 40.2% in the 1st quarter. Alpine Associates Management Inc. now owns 5,554,400 shares of the technology company’s stock valued at $128,694,000 after purchasing an additional 1,593,766 shares during the last quarter. ARP Americas LP lifted its stake in Finisar by 274.8% during the 1st quarter. ARP Americas LP now owns 996,498 shares of the technology company’s stock worth $23,089,000 after acquiring an additional 730,646 shares in the last quarter. IndexIQ Advisors LLC boosted its holdings in Finisar by 28.5% during the 1st quarter. IndexIQ Advisors LLC now owns 1,760,414 shares of the technology company’s stock valued at $40,789,000 after acquiring an additional 390,313 shares during the period. State of Wisconsin Investment Board grew its holdings in shares of Finisar by 127.0% in the first quarter. State of Wisconsin Investment Board now owns 603,200 shares of the technology company’s stock valued at $13,976,000 after purchasing an additional 337,500 shares in the last quarter. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in Finisar during the 1st quarter worth approximately $3,985,000. Institutional investors own 99.70% of the company’s stock.

FNSR stock traded up $0.50 during midday trading on Wednesday, hitting $23.25. 870,253 shares of the stock were exchanged, compared to its average volume of 1,433,294. Finisar Co. has a fifty-two week low of $15.81 and a fifty-two week high of $24.77. The stock has a market cap of $2.76 billion, a price-to-earnings ratio of 39.41, a PEG ratio of 2.60 and a beta of 1.52. The stock’s 50-day moving average price is $22.91 and its 200-day moving average price is $23.09. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.38 and a current ratio of 6.84.

Finisar (NASDAQ:FNSR) last announced its quarterly earnings data on Thursday, June 13th. The technology company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.04. Finisar had a negative net margin of 3.48% and a positive return on equity of 4.62%. The business had revenue of $310.09 million for the quarter, compared to the consensus estimate of $323.42 million. Research analysts anticipate that Finisar Co. will post 0.73 EPS for the current year.

Several research firms recently commented on FNSR. Stifel Nicolaus set a $23.00 target price on Finisar and gave the stock a “hold” rating in a research note on Friday, June 14th. BidaskClub cut Finisar from a “buy” rating to a “hold” rating in a research note on Wednesday, August 28th. MKM Partners lowered their price target on Finisar from $23.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, September 5th. Finally, B. Riley reaffirmed a “neutral” rating on shares of Finisar in a research report on Friday, June 14th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $26.31.

Finisar Profile

Finisar Corporation provides components and subsystems to networking equipment manufacturers, data center operators, telecom service providers, consumer electronics, and automotive companies in the United States, China, Malaysia, and internationally. The company’s optical subsystems primarily include transmitters, receivers, transceivers, transponders, and active optical cables, which provide the fundamental optical-electrical or optoelectronic interface for interconnecting the electronic equipment used in wireline networks comprising switches, routers, and servers, as well as wireless networks, such as antennas and base stations.

Featured Article: What do I need to know about analyst ratings?

Institutional Ownership by Quarter for Finisar (NASDAQ:FNSR)

Receive News & Ratings for Finisar Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Finisar and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Ulta Beauty (NASDAQ:ULTA) Lowered to Equal Weight at Morgan Stanley

Vanguard Group Inc. increased its position in shares of Ulta Beauty by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 5,897,787 shares …

Ulta Beauty logoUlta Beauty (NASDAQ:ULTA) was downgraded by Morgan Stanley from an “overweight” rating to an “equal weight” rating in a research report issued on Friday, August 30th, Marketbeat.com reports. They presently have a $275.00 target price on the specialty retailer’s stock, down from their previous target price of $395.00. Morgan Stanley’s target price points to a potential upside of 17.98% from the stock’s previous close.

A number of other equities analysts have also weighed in on ULTA. Oppenheimer set a $390.00 price objective on Ulta Beauty and gave the company a “buy” rating in a research note on Wednesday, August 21st. Zacks Investment Research upgraded Ulta Beauty from a “hold” rating to a “buy” rating and set a $384.00 price objective on the stock in a report on Monday, May 20th. UBS Group boosted their target price on Ulta Beauty from $370.00 to $390.00 and gave the stock a “top pick” rating in a report on Thursday, July 25th. BidaskClub cut Ulta Beauty from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, Guggenheim reissued a “buy” rating and issued a $375.00 target price (up previously from $350.00) on shares of Ulta Beauty in a research report on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $303.10.

Ulta Beauty stock traded down $3.61 during midday trading on Friday, reaching $233.10. 1,950,187 shares of the stock traded hands, compared to its average volume of 2,155,693. The stock’s fifty day moving average is $322.65 and its 200-day moving average is $335.37. The stock has a market cap of $13.93 billion, a P/E ratio of 21.48, a PEG ratio of 1.15 and a beta of 1.07. Ulta Beauty has a 12 month low of $224.43 and a 12 month high of $368.83. The company has a quick ratio of 0.74, a current ratio of 1.80 and a debt-to-equity ratio of 0.90.

Ulta Beauty (NASDAQ:ULTA) last announced its earnings results on Thursday, August 29th. The specialty retailer reported $2.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.79 by ($0.03). The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.68 billion. Ulta Beauty had a net margin of 9.86% and a return on equity of 36.87%. The firm’s revenue was up 12.0% compared to the same quarter last year. During the same period last year, the business posted $2.46 EPS. On average, equities analysts predict that Ulta Beauty will post 11.81 EPS for the current fiscal year.

In related news, Director Sally E. Blount sold 315 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $359.28, for a total transaction of $113,173.20. Following the completion of the sale, the director now directly owns 989 shares of the company’s stock, valued at approximately $355,327.92. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Lorna Nagler sold 2,000 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $354.03, for a total transaction of $708,060.00. Following the transaction, the director now owns 8,368 shares of the company’s stock, valued at $2,962,523.04. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in ULTA. Vanguard Group Inc. increased its position in shares of Ulta Beauty by 0.5% during the 2nd quarter. Vanguard Group Inc. now owns 5,897,787 shares of the specialty retailer’s stock worth $2,045,883,000 after purchasing an additional 26,998 shares in the last quarter. BlackRock Inc. grew its holdings in Ulta Beauty by 5.3% during the 2nd quarter. BlackRock Inc. now owns 4,166,032 shares of the specialty retailer’s stock worth $1,445,154,000 after acquiring an additional 207,927 shares during the last quarter. FMR LLC grew its holdings in Ulta Beauty by 15.3% during the 1st quarter. FMR LLC now owns 2,262,297 shares of the specialty retailer’s stock worth $788,932,000 after acquiring an additional 300,904 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Ulta Beauty by 13.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,774,253 shares of the specialty retailer’s stock worth $615,471,000 after acquiring an additional 210,475 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Ulta Beauty by 46.1% during the 2nd quarter. Invesco Ltd. now owns 1,532,011 shares of the specialty retailer’s stock worth $531,439,000 after acquiring an additional 483,342 shares during the last quarter. Hedge funds and other institutional investors own 88.92% of the company’s stock.

Ulta Beauty Company Profile

Ulta Beauty, Inc operates as a beauty retailer in the United States. The company’s stores offer cosmetics, fragrances, skincare and haircare products, bath and body products, and salon styling tools; salon services, including hair, skin, makeup, and brow services; and others, including nail products and accessories.

Further Reading: What is a Real Estate Investment Trust (REIT)?

Analyst Recommendations for Ulta Beauty (NASDAQ:ULTA)

Receive News & Ratings for Ulta Beauty Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ulta Beauty and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts